Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...

詳細記述

保存先:
書誌詳細
出版年:Eur J Haematol
主要な著者: Wagner, Sandro M., Melchardt, Thomas, Egle, Alexander, Magnes, Teresa, Skrabs, Cathrin, Staber, Philipp, Simonitsch‐Klupp, Ingrid, Panny, Michael, Lehner, Barbara, Greil, Richard, Keil, Felix, Jäger, Ulrich, Sillaber, Christian
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://ncbi.nlm.nih.gov/pubmed/31838747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料